Karl F Mann
Overview
Explore the profile of Karl F Mann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shmulewitz D, Aharonovich E, Witkiewitz K, Anton R, Kranzler H, Scodes J, et al.
Am J Psychiatry
. 2021 Jan;
178(6):548-559.
PMID: 33472388
Objective: Little is known about change over time in the prevalence of World Health Organization (WHO) risk drinking levels (very high, high, moderate, low) and their association with health conditions,...
2.
Witkiewitz K, Kranzler H, Hallgren K, Hasin D, Aldridge A, Zarkin G, et al.
J Gen Intern Med
. 2020 Nov;
36(2):404-412.
PMID: 33180306
Background: The World Health Organization (WHO) categorizes alcohol consumption according to grams consumed into low-, medium-, high-, and very-high-risk drinking levels (RDLs). Although abstinence has been considered the ideal outcome...
3.
Witkiewitz K, Heather N, Falk D, Litten R, Hasin D, Kranzler H, et al.
Addiction
. 2020 Feb;
115(9):1668-1680.
PMID: 32056311
Aims: To examine whether World Health Organization (WHO) risk-level reductions in drinking were achievable, associated with improved functioning and maintained over time among patients at varying initial alcohol dependence severity...
4.
Witkiewitz K, Falk D, Litten R, Hasin D, Kranzler H, Mann K, et al.
Alcohol Clin Exp Res
. 2019 Apr;
43(5):979-987.
PMID: 30951210
Background: Reductions in the World Health Organization (WHO) risk drinking levels have been proposed as an alternative primary outcome for alcohol clinical trials. Yet, little is known about whether reductions...
5.
Falk D, OMalley S, Witkiewitz K, Anton R, Litten R, Slater M, et al.
JAMA Psychiatry
. 2019 Mar;
76(4):374-381.
PMID: 30865232
Importance: The US Food and Drug Administration recognizes total abstinence and no heavy drinking days as outcomes for pivotal pharmacotherapy trials for alcohol use disorder (AUD). Many patients have difficulty...
6.
Witkiewitz K, Kranzler H, Hallgren K, OMalley S, Falk D, Litten R, et al.
Alcohol Clin Exp Res
. 2018 Nov;
42(12):2453-2465.
PMID: 30395350
Background: Abstinence and no heavy drinking days are currently the only Food and Drug Administration-approved end points in clinical trials for alcohol use disorder (AUD). Many individuals who fail to...
7.
Litten R, Falk D, OMalley S, Witkiewitz K, Mann K, Anton R
Alcohol Clin Exp Res
. 2017 May;
41(7):1381-1382.
PMID: 28471501
No abstract available.
8.
Witkiewitz K, Wilson A, Pearson M, Hallgren K, Falk D, Litten R, et al.
Alcohol Clin Exp Res
. 2017 Mar;
41(5):1054-1062.
PMID: 28295414
Background: Recently, the Food and Drug Administration (FDA) proposed to expand the options for primary end points in the development of medications for alcohol use disorder to include either abstinence...
9.
Frischknecht U, Hermann D, Tunc-Skarka N, Wang G, Sack M, Van Eijk J, et al.
Alcohol Clin Exp Res
. 2017 Jan;
41(2):323-333.
PMID: 28098946
Background: Both chronic alcohol consumption and alcohol withdrawal lead to neural tissue damage which partly recovers during abstinence. This study investigated withdrawal-associated changes in glutamatergic compounds, markers of neuronal integrity,...
10.
Juhas M, Sun H, Brown M, MacKay M, Mann K, Sommer W, et al.
Neuroimage
. 2017 Jan;
148:115-122.
PMID: 28065850
Purpose: Evaluate brain iron accumulation in alcohol use disorder (AUD) patients compared to controls using quantitative susceptibility mapping (QSM). Methods: QSM was performed retrospectively by using phase images from resting...